FDA Approves Subcutaneous Leqembi IQLIK as Initiation Dose for Early Alzheimer Disease
KEY TAKEAWAYS
- The FDA approved Leqembi IQLIK as a once-weekly subcutaneous initiation dose for adults with early Alzheimer disease, expanding use beyond maintenance therapy.
- The subcutaneous autoinjector demonstrated pharmacokinetic exposure, efficacy, safety, and biomarker effects comparable to IV lecanemab, supporting the FDA approval.
- The new formulation may reduce treatment burden and improve access by allowing patients to initiate therapy without routine IV infusions, while standard ARIA monitoring recommendations remain in place.
The Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for Leqembi IQLIK (lecanemab-irmb; Eisai, Tokyo, Japan; Biogen, Cambridge, MA) as a once-weekly subcutaneous initiation dose for adults with early Alzheimer disease. The approval expands the product's indication beyond the previously approved maintenance regimen, allowing eligible patients to begin treatment with a subcutaneous autoinjector rather than intravenous (IV) infusions. The decision was supported by pharmacokinetic, efficacy, safety, and biomarker data demonstrating that the subcutaneous formulation provides exposure comparable to IV lecanemab.
Leqembi IQLIK is administered as a once-weekly subcutaneous injection using an autoinjector that delivers the dose in approximately 15 seconds. According to Eisai and Biogen, the new option is intended to reduce treatment burden, improve convenience, and expand access by reducing dependence on infusion centers. The approval follows the FDA's 2025 authorization of Leqembi IQLIK for maintenance dosing after 18 months of IV therapy and now allows clinicians to use the subcutaneous formulation throughout treatment.
The approval coincides with data presented at the 2026 Alzheimer's Association International Conference (AAIC), where investigators reported that patients who transitioned from IV to subcutaneous Leqembi maintained clinical benefit through 36 months while reporting high treatment satisfaction and a strong preference for subcutaneous administration. Together, the regulatory decision and emerging real-world evidence suggest that subcutaneous administration may make long-term anti-amyloid therapy more practical for patients, caregivers, and treatment centers.
What Does This Mean for Practice?
Clinicians should note that the prescribing information, including recommendations for amyloid-related imaging abnormality (ARIA) monitoring and patient selection, remains consistent with IV lecanemab.
Source
Eisai Co, Ltd, Biogen Inc. FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease. Published July 13, 2026. Accessed July 14, 2026.